Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Analgesic agents under development at Banyu

Aug. 18, 2000

Lundbeck's siramesine enters phase II development

Aug. 18, 2000

Merz and Lundbeck to develop and market memantine for various CNS indications

Aug. 18, 2000

Palatin Technologies awarded phase I SBIR grant for pain management therapies

Aug. 18, 2000

Novel AMPA antagonists under study at Kyorin

Aug. 17, 2000

New selective 5-HT3 antagonists useful as antiemetics

Aug. 17, 2000

EpiCept to begin clinical development of cancer pain therapy

Aug. 17, 2000

New compounds interacting with GABA receptor useful for anxiety, etc.

Aug. 16, 2000

New compounds interacting with NK1 receptor useful for pain, etc.

Aug. 16, 2000

Synaptic vesicle transporter for glutamate discovered: VGLUT1

Aug. 16, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...